Last reviewed · How we verify

IV efgartigimod — Competitive Intelligence Brief

IV efgartigimod (IV efgartigimod) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: FcRn inhibitor. Area: Immunology.

marketed FcRn inhibitor Neonatal Fc receptor (FcRn) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

IV efgartigimod (IV efgartigimod) — Rambam Health Care Campus. Efgartigimod is an IgG Fc receptor inhibitor that reduces circulating immunoglobulin G (IgG) antibodies by blocking their recycling through the neonatal Fc receptor (FcRn).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IV efgartigimod TARGET IV efgartigimod Rambam Health Care Campus marketed FcRn inhibitor Neonatal Fc receptor (FcRn)
ARGX-113 ARGX-113 argenx phase 3 FcRn inhibitor FcRn (neonatal Fc receptor)
Nipocalimab SC-LIV Nipocalimab SC-LIV Janssen Research & Development, LLC phase 3 FcRn inhibitor Neonatal Fc receptor (FcRn)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (FcRn inhibitor class)

  1. Janssen Research & Development, LLC · 1 drug in this class
  2. Rambam Health Care Campus · 1 drug in this class
  3. argenx · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IV efgartigimod — Competitive Intelligence Brief. https://druglandscape.com/ci/iv-efgartigimod. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: